RBC Raises Aurinia Pharmaceuticals Price Target to $18 From $16
RBC kept its Sector Perform rating on Aurinia Pharmaceuticals and maintained its speculative-risk designation.
Related stories
Oracle Shares Fall After Announcing Stock and Bond Transactions
Oracle announced stock transactions and bond transactions; its shares fell.
L impact | EQUITY | Nov 02, 2026, 01:56 PM UTC
Check Point Software Sees Q4 Revenue of $720M-$770M
M impact | EQUITY | Nov 02, 2026, 01:48 PM UTC
Cyberattack on Refrigeration Systems Hits European Supermarkets
A cyberattack on refrigeration systems affected supermarkets across Europe.
M impact | EQUITY | Nov 02, 2026, 01:48 PM UTC
Fox Reports Higher Q1 FY27 EPS and Revenue
Fox reported year-over-year increases in Q1 FY27 earnings per share and revenue.
M impact | EQUITY | Nov 02, 2026, 01:47 PM UTC
IDEXX Executive Says Covet Revenue Run Rate Is About $20 Million
An IDEXX executive said Covet revenue is growing at strong double-digit rates.
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC
Infineon and Qualcomm Technologies Sign Automated Driving Agreement
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC